Analysis
Bridge to Life has closed $110 million in Series C equity funding, plus additional debt financing, for its organ preservation and perfusion systems, according to Tech Startups' funding roundup covering August 13 deal activity.
The company's core technology extends how long a donor organ stays viable between recovery and transplant -- perfusion systems that keep organs at controlled temperature and oxygenation rather than relying on simple cold storage, the decades-old default that limits most kidneys, livers and hearts to a narrow window before they're no longer usable. Every additional hour of viability matters clinically: it expands the geographic radius over which an organ can be matched to a recipient, gives transplant teams more time to run compatibility testing, and reduces the number of viable organs that go unused because a match couldn't be found in time.
## A strong year for biotech capital, in a different lane The round lands inside a genuinely strong year for biotech venture financing. Crunchbase's 2026 tracking shows drug-discovery and longevity-adjacent AI companies topping the private-financing leaderboard:
“## A strong year for biotech capital, in a different lane The round lands inside a genuinely strong year for biotech venture financing.”
- Isomorphic Labs -- $2.1 billion, the largest 2026 biotech round so far
- Earendil Labs -- $787 million
- NewLimit -- $435 million
- Chai Discovery -- $400 million
Those four are drug-discovery and longevity-adjacent AI companies, a different category from Bridge to Life's medical-device and perfusion-hardware focus. Therapeutics discovery platforms are capturing the bulk of disclosed biotech capital this year, per Crunchbase, which makes Bridge to Life's device-focused round a comparatively smaller but still meaningful bet on a narrower, more mechanical problem: keeping an organ alive outside a body long enough to get it where it needs to go.
Bridge to Life's closest competitive comparisons are perfusion companies like TransMedics, which built a public-market business on a similar organ-care-system model and has demonstrated that hospitals will pay a premium for extended organ viability when it measurably improves transplant outcomes. A $110 million round gives Bridge to Life real runway to scale manufacturing and clinical adoption without needing to prove the underlying science from scratch -- perfusion-based preservation is already an established clinical category, which lowers the round's execution risk relative to a novel-mechanism biotech bet.
What the funding announcement doesn't specify is the debt financing's size or terms, which matters for understanding the company's actual capital structure and how much equity dilution founders and early investors are absorbing relative to the total capital raised.
The next marker to watch is FDA clearance or expansion milestones for whichever organ category -- kidney, liver or heart -- the new capital is earmarked to scale first, since perfusion systems typically clear organ-by-organ rather than as a single blanket approval.
